Get the Stockscreener App
7.98
0.88%
0.07
Dbv Technologies Adr stock is traded at $7.98, with a volume of 58,041.
It is up +0.88% in the last 24 hours and up +70.51% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$7.91
Open:
$7.91
24h Volume:
58,041
Relative Volume:
0.15
Market Cap:
$212.95M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-7.60
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+10.99%
1M Performance:
+70.51%
6M Performance:
+121.67%
1Y Performance:
+17.35%
1-Day Range:
$7.6505
$8.44
1-Week Range:
$6.83
$8.44
52-Week Range:
$2.2045
$8.50
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
7.98 | 212.95M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) & Vaxcyte (NASDAQ:PCVX) Critical Contrast - Defense World
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - Informazione.it
DBV Technologies S.A. SEC 10-K Report - TradingView
DBV Technologies Completes Dual-Market Financial Filings for 2024 - Stock Titan
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European ADRs Show Mixed Fortunes In US Market - Finimize
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
European ADRs See Mixed Results With Biopharma Leading Gains - Finimize
Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Benzinga
DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - MSN
DBV Technologies’ Momentum: Will It Last? - timothysykes.com
DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire
Major Breakthrough: $306.9M Funding Powers Revolutionary Peanut Allergy Patch to FDA Finish Line - Stock Titan
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
DBV Technologies faces cash shortage, stock drops By Investing.com - Investing.com South Africa
DBV Technologies faces cash shortage, stock drops - Investing.com
Major FDA Breakthrough: DBV's Peanut Allergy Treatment Path Accelerates Despite Cash Concerns - Stock Titan
DBV Technologies Secures Agreement with FDA on Safety - GlobeNewswire
REG-DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials By Investing.com - Investing.com South Africa
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials - Investing.com
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
JMP reiterates DBV Technologies stock with $10 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
DBV Technologies (DBVT) to Release Earnings on Thursday - Defense World
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):